Washington Doctors Successfully Treat Coronavirus Patient – Results Seen in hours, Patient Sent Home

https://www.theverge.com/2020/2/4/21122327/coronavirus-experimental-medication-treatment-wuhan-china-gilead-hiv

Excerpt: 

It’s not clear if the medication, called remdesivir, actually helped the patient, or if his improvement was a coincidence. But it’s one of a few drugs, including a combination of anti-HIV drugs, that doctors think might help patients with the new coronavirus.

Ironically, the antivirus was created by the pharmaceutical company Gilead as a treatment for Ebola.

The article states the drug didn’t do much for Ebola but a larger clinical trial on coronavirus patients is underway:  https://www.bioworld.com/articles/432804-gileads-remdesivir-enters-china-phase-iii-trial-to-fight-coronavirus

Excerpt:

The study, expected to be completed on April 27, is a phase III randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of remdesivir in hospitalized adult patients with mild and moderate 2019-nCoV infections. It will enroll 270 patients and be carried out in the China-Japan Friendship Hospital in Beijing.

Remdesivir is not approved by the Food and Drug Administration but has gone through safety testing during the Ebola outbreak and why Gilead is able to test it in sick patients.

_________________

For more:  https://www.pnas.org/content/early/2020/02/12/1922083117

Excerpt:

We tested the efficacy of the broad-acting antiviral remdesivir in the rhesus macaque model of MERS-CoV (Middle East Respiratory Syndrome) infection. Remdesivir reduced the severity of disease, virus replication, and damage to the lungs when administered either before or after animals were infected with MERS-CoV. Our data show that remdesivir is a promising antiviral treatment against MERS that could be considered for implementation in clinical trials. It may also have utility for related coronaviruses such as the novel coronavirus 2019-nCoV emerging from Wuhan, China.